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Abstract
We applied whole-genome single-nucleotide polymorphism
arrays to define a comprehensive genetic profile of 23
esophageal adenocarcinoma (EAC) primary tumor biopsies
based on loss of heterozygosity (LOH) and DNA copy number
changes. Alterations were common, averaging 97 (range,
23–208) per tumor. LOH and gains averaged 33 (range, 3–83)
and 31 (range, 11–73) per tumor, respectively. Copy neutral
LOH events averaged 27 (range, 7–57) per EAC. We noted 126
homozygous deletions (HD) across the EAC panel (range, 0–11
in individual tumors). Frequent HDs within FHIT (17 of 23),
WWOX (8 of 23), and DMD (6 of 23) suggest a role for common
fragile sites or genomic instability in EAC etiology. HDs were
also noted for known tumor suppressor genes (TSG), including
CDKN2A, CDKN2B, SMAD4 , and GALR1 , and identified PDE4D
and MGC48628 as potentially novel TSGs. All tumors showed
LOH for most of chromosome 17p, suggesting that TSGs other
than TP53 may be targeted. Frequent gains were noted around
MYC (13 of 23), BCL9 (12 of 23), CTAGE1 (14 of 23), and ZNF217
(12 of 23). Thus, we have confirmed previous reports indica-
ting frequent changes to FHIT, CDKN2A, TP53, and MYC in
EAC and identified additional genes of interest. Meta-analysis
of previous genome-wide EAC studies together with the data
presented here highlighted consistent regions of gain on 8q,
18q, and 20q and multiple LOH regions on 4q, 5q, 17p, and 18q,
suggesting that more than one gene may be targeted on each of
these chromosome arms. The focal gains and deletions
documented here are a step toward identifying the key genes
involved in EAC development. [Cancer Res 2008;68(11):4163–72]
Introduction
During the past 3 decades, there have been significant increases
in the incidence of esophageal adenocarcinoma (EAC). In the
United States, rates have risen faster than any other cancer (1–3),
with similar increases documented in Europe (4, 5) and Australia
(6, 7). With the increasing prevalence of contributing factors
(i.e., obesity and acid reflux; ref. 8) in developed societies, it is
predicted that EAC incidence will continue to rise, posing an
escalating health burden. Better understanding of the genes
involved, combined with increased knowledge of risk factors,
may lead to improved screening and treatment. Although
candidate screening approaches have implicated a few genes
related to EAC development (reviewed in ref. 9), few studies have
conducted detailed analyses on a genome-wide scale.
DNA copy number changes frequently contribute to tumor
progression. Loss of tumor suppressor genes (TSGs), such as
CDKN2A and TP53 , commonly occurs in cancerous and precan-
cerous conditions, including those of the esophagus (reviewed
in ref. 10). In other genomic regions, copy number gain leads to
the increased activity of oncogenes (e.g., MYC), which promote
autonomous cell growth. Numerous TSGs and oncogenes have
been shown to have a wide range of cellular functions and cancer
specificities. There is little doubt that additional genes with roles in
tumorigenesis await identification and whole-genome methodolo-
gies offer a powerful means to identify such genes.
Several studies have applied low-resolution comparative ge-
nomic hybridization (CGH) methodologies to investigate DNA copy
number alterations in EAC (11–13). This technology adequately
detects high-level amplifications and homozygous deletions (HDs)
but underestimates loss of heterozygosity (LOH; ref. 14). The
application of high-density single-nucleotide polymorphism (SNP)
microarrays to define genome-wide copy number changes provides
superior resolution and combines the advantages of both CGH and
LOH methodologies, allowing the detection of copy neutral LOH
(NLOH) events (15, 16). Here, SNP arrays were used to generate
high-resolution DNA copy number profiles in a panel of primary
EAC tumor biopsies.
Materials and Methods
Biopsy collection and DNA extraction. Approval to undertake the
study was obtained from the research ethics committees of the Queensland
Institute of Medical Research and participating hospitals. Written informed
consent to participate was obtained from all patients. Primary EAC biopsies
were taken from 26 patients (25 male and 1 female) before treatment. A
biopsy of normal squamous esophageal epithelium from one patient was
used as a reference sample. Biopsies were placed in RNAlater (Ambion)
immediately on collection and left at 4jC overnight. Samples were then
stored at 20jC before removal of excess RNAlater before storage at
70jC. DNA and RNA were simultaneously extracted using Qiagen
AllPrep extraction kits via the Tissue Lyser–based protocol according
Note: Supplementary data for this article are available at Cancer Research Online
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to the manufacturer’s instructions (Qiagen). Diagnosis was confirmed by
pathologic review (by A.D.C.) of a separate biopsy taken from the same
lesion (n = 17, usually at the same level of the esophagus) or by clinical
review (n = 9). Patient information was collected through self-completed,
mailed questionnaires and clinical chart review (8); salient features are
summarized in Table 1.
SNP microarray preparations. The Infinium II Assay was done using
Illumina Sentrix HumanHap300 BeadChips (317K, TagSNP Phase I, v1.1)
according to the manufacturer’s specifications (Illumina). Briefly, 750 ng of
genomic DNA were amplified at 37jC overnight using solutions WG-AMM
and WG-MP1, following which the amplified DNA was fragmented using
solution WG-FRG and precipitated with isopropanol after the addition of
WG-PA1. Dried pellets were then resuspended in WG-RA1 and hybridized to
beadchips along with WG-RA1 and formamide. Arrays were incubated
overnight at 48jC, after which they underwent single-base extension on a
TeFlow Chamber Rack system (Tecan) using solutions WG-XC1, WG-XC2,
and WG-TEM. Following which, they were stained with WG-LTM and
WG-ATM, dried for 1 h, and then imaged using a BeadArray Reader
(Illumina). Image data were analyzed using BeadStudio 2.0 (Illumina). For
additional details and example outputs, refer to Peiffer and colleagues (17).
All genomic positions were based on hg17 from the University of California
at Santa Cruz (UCSC) Genome Browser.8
Compilation of individual EAC profiles. BeadStudio 2.0 software was
used to generate whole-genome profiles for the tumors. Each EAC was
referenced against a sample of normal squamous epithelium. As noted
previously (17), this approach provided more consistent logR ratios
compared with using the common reference pool provided by Illumina.
We compared this squamous sample against the Illumina reference pool
and found it to have a normal 2n DNA complement, with the exception of a
very small region of amplification within chromosomal band 6q27. Thus,
SNPs mapping within the 6q27 chromosomal band were excluded from
analysis. Because the HumanHap300 Genotyping BeadChip only includes
two SNPs that map to the Y chromosome, we also excluded this
chromosome from our analyses. The process EAC and squamous reference
data files are in the Gene Expression Omnibus, series GSE10506.
Initially, we used the autoscoring procedures built into BeadStudio 2.0
(LOH score and copy number variation algorithms); however, these yielded
inconsistent output in the presence of nontumor tissue contamination.
Thus, all DNA copy number regions were annotated manually by one of us
(D.J.N.) and confirmed by another (H.Y.H.) with the aid of our Simulated
DNA Copy Number (SiDCoN) tool (18). Any discrepancies between scorers
were discussed and consensus was reached. With the exception of HD and
4n gain events (which both have normal Ballele profiles but grossly altered
logR values), we did not score DNA changes if Ballele plots indicated that
<30% of cells were involved, as described previously (18). DNA copy number
changes for all samples were converted using Excel into custom data tracks
for the UCSC Genome Browser.
Estimations of tumor cell density in biopsy samples. Tumor biopsies
contain a variable amount of normal tissue. High levels of nontumor tissue
Table 1. Demographic details for 26 EAC biopsy patients
Patient no. Sex Age at diagnosis Survival (d) Status Postoperative stage Diagnosis* Tumor % by LOH only
c
40357 M 66 466 Alive III Slide review 28
53111 M 66 70 Alive Not staged Pathology report 30
40327 M 70 666 Alive III Pathology report 30
40323 M 60 531 Dead IVA Slide review 51
40353 M 63 536 Alive III Slide review 54
40359 M 55 469 Alive I Slide review 58
40358 M 56 408 Dead IVA Slide review 58
40340 M 66 329 Dead IV Slide review 59
40362 M 65 183 Dead IVA Slide review 61
54043 M 73 1,130 Alive II Pathology report 63
40331 M 65 600 Alive with disease III Pathology report 63
42199 F 74 634 Alive IIA Pathology report 65
40361 M 75 282 Dead III Slide review 67
54014 M 80 367 Dead Not staged Pathology report 67
53048 M 70 1,153 Alive II Pathology report 67
40356 M 78 489 Dead III Slide review 69
40341 M 79 391 Dead III Slide review 78
40363 M 69 462 Alive I Pathology report 78
40334 M 68 607 Alive IIA Slide review 78
40325 M 62 657 Dead IIA Slide review 84
40338 M 72 53 Dead IVB Slide review 85
40320 M 62 699 Alive IIB Slide review 87
53145 M 52 878 Alive IV Pathology report 88
40360 M 78 452 Alive IIA Slide review 89
40364 M 71 287 Dead IVA Slide review 90
40345 M 61 547 Dead III Slide review 91
* EAC diagnosis was confirmed by review of a H&E slide made from a tumor biopsy from the same esophageal level as the DNA sample biopsy (slide
review). Where this was not possible, diagnosis was confirmed through review of the existing pathology report. In all cases, the review was conducted by
the same experienced pathologist (A.D.C.).
cDetermined from the Ballele fraction in designated LOH regions using SiDCoN (18).
8 http://genome.ucsc.edu/
Cancer Research
Cancer Res 2008; 68: (11). June 1, 2008 4164 www.aacrjournals.org
interfere with DNA copy number interpretations of tumor samples. We
thus estimated the tumor fraction of each biopsy using the following
procedure: regions of LOH were identified manually; the level of Ballele
involvement was determined within each of these regions by exporting the
Ballele data for each sample from BeadStudio; using an R script, Ballele
values <0.5 were inverted, providing plots ranging from 0.5 to 1 (this step
essentially doubles the density of the Ballele signal intensity measures,
providing more accurate estimates, particularly for shorter DNA copy
number changes); and a smoothed binary segregation algorithm (19) was
then applied, across each chromosome, to the modified Ballele values
<0.97 (polymorphic SNPs), generating regionally normalized data for each
SNP. Another R script was then used to identify the SNPs that mapped
within each LOH event and average the normalized Ballele values within
the appropriate tumor sample. Using SiDCoN (18), we then estimated the
tumor involvement within each of these events. Across each sample, the
LOH events with the highest tumor involvement were assumed to
approximate the total fraction of tumor in each sample. This procedure
assumes that contaminating nontumor tissue has a normal 2n DNA
complement. The result of this analysis (presented in Table 1) showed that
3 of our 26 EAC biopsies contained <50% tumor material. These samples
were excluded from further study because the Illumina platform has been
found insensitive when tumor content drops below this level (17). The
remaining 23 EAC biopsies contained 50% to 90% tumor cells based on the
strongest LOH changes.
Median logR plots. Sample-specific logR data were exported from
BeadStudio 2.0 for the 23 EAC biopsies with >50% tumor cells, as described
above. R scripts were used to apply a smoothed binary segregation
algorithm (19) to these data for each sample across each chromosome.
These data were then compiled to generate median (smoothed) logR values
across each data point.
Results
Sample details. Average age at diagnosis was 67 years (range,
52–80). The cohort included two stage I, seven stage II, eight stage
III, and seven stage IV patients based on postoperative staging,
with patient survival times ranging from 53 to 699 days and a
minimum follow-up time of 70 days for surviving patients.
Consistent with the previous genome-wide array studies (11–13),
Table 2. Key regions of DNA copy number change in 23 EAC biopsies
Region in hg17 Size (Mb) Chromosomal band DNA alterations Possible genes of note
A. Regions of fewest changes
chr1:1,300,001-7,300,000 6.0 1p36.32 9 changes p36.3 breakpoint, TP73, DFFB
chr10:76,700,001-81,900,000 5.2 10q23.3 9 changes
chr11:102,400,001-115,000,000 12.6 11q22.3-q23.1 10 changes Includes CASP4, CASP5, CASP1 , and ATM gene
chr16:6,300,001-11,300,000 5.0 16p13.2 10 changes
B. Most common gain (AMP) regions (smallest region or overlap is indicated)
chr18:18,180,001-18,280,000 0.1 18q11.2 14 AMPs CTAGE1
chr8:101,100,001-104,000,000 2.9 8q22.3 13 AMPs MYBL1
chr8:128,100,001-129,100,000 1.0 8q24.21 13 AMPs MYC
chr8:130,500,001-132,000,000 1.5 8q24.21 13 AMPs MLZE, DDEF1
chr1:143,700,001-144,900,000 1.2 1q21.1 12 AMPs BCL9
chr1:151,000,001-155,000,000 4.0 1q22 12 AMPs SKI
chr20:49,100,001-52,300,000 3.2 20q13.2 12 AMPs ZNF217
C. Most common LOH regions (smallest region or overlap is indicated)
chr18:42,300,001-49,000,000 6.7 18q21.1 18 LOHs (HD region)
chr18:54,600,001-58,000,000 3.4 18q21.32 18 LOHs (HD region) MC4R
chr17:1-20,774,742 20.8 17p 16-15 LOHs Many including TP53, MYBBP1A
chr5:55,000,000-93,500,000 38.5 5q11.2-q14.3 14 LOHs (HD region) Many including PDE4D
chr11:2,400,000-5,900,000 3.5 11p15.4 14 LOHs Many including CDKN1C
D. Most common regions of shared copy NLOH (smallest region or overlap is indicated)
chr2:10,000,000-85,000,000 75.0 2p24.3-p12 11 NLOHs Many including MSH2, MYCN
chr2:230,000,001-238,400,000 8.4 2q37 10 NLOHs Many
chr9:134,500,001-137,500,000 3.0 9q34.3 10 NLOHs Many including TSC1
chr17:6,800,000-7,700,000 0.9 17p13.1 10 NLOHs Many including TP53
chr17:400,000-1,400,000 1.0 17p13.3 10 NLOHs Many
chr17:74,800,000-77,000,000 2.2 17q25.3 10 NLOHs Many
E. Most common regions of HD (smallest region or overlap is indicated)
chr3:60,310,078-60,712,164 0.4 3p14.2 17 HDs Within FHIT
chr16:76,691,052-77,804,064 1.1 16q23.2 8 HDs Within WWOX
chr9:21,580,000-22,600,000 1.0 9p21.3 6 HDs Includes MTAP, CDKN2A, CDKN2B, C9orf53, DMRTA1
chrX:30,898,403-32,989,184 2.1 Xp21.2 6 HDs Within DMD
chr4:91,513,360-92,060,333 0.5 4q22.1 5 HDs Within MGC48628
chr18:46,700,000-46,950,000 0.3 18q21.1 4 HDs Includes ME2, ELAC1, SMAD4
chr18:72,900,000-73,900,000 1.0 18q23 4 HDs Includes MBP, GALR1
chr5:58,306,241-59,819,647 1.5 5q11.2-q12.1 3 HDs Within PDE4D
chr18:56,050,001-56,400,000 0.3 18q21.32 3 HDs Includes MC4R
chr9:24,300,000-25,800,000 1.5 9p21.3-p21.2 2 HDs No genes
chr20:14,500,000-15,536,000 1.0 20p21.1 2 HDs Includes 20orf133, BBC018687
chr21:21,500,001-25,000,000 3.5 21q21.1-q21.2 2 HDs Includes NCAM2, FLJ42200
Genome-Wide Copy Number Analysis in EAC
www.aacrjournals.org 4165 Cancer Res 2008; 68: (11). June 1, 2008
and most EAC publications, our cohort has a strong male bias. As
expected, the postoperative staging correlates significantly with
patient survival [P = 0.0136, Cox proportional hazards (CPH)],
whereas age (P = 0.1336, CPH) and the nontumor content of the
biopsy (P = 0.2304, CPH) do not.
Types and numbers of DNA copy number changes. We
observed 2,229 DNA copy number changes across all 23 EAC
samples, an average of 97 per tumor (range, 23–208; Supplementary
Table S1). Within these changes, 20% to 90% of the genome showed
a change in DNA copy number in each EAC biopsy. This suggests a
high background rate, with at least 39% (9 of 23) of our EAC
primary tumor panel showing DNA copy number changes at any
autosomal point. The genomic regions with the least number of
changes were 1p36.32 and 10q23.3 with 9 changes and 11q22.3 and
16p13.2 with 10 changes (Table 2A). In each case, the type of
changes seen was a roughly even mix of losses, NLOH, and gains,
with the exception of 11q22.3, which was mostly LOH (8 of 10).
The most common changes were LOH and gains, with averages
of 33 (range, 3–83) and 31 (range, 11–73) per EAC, respectively
(Supplementary Table S1). SNP arrays allow the detection of copy
NLOH (15, 16), which was surprisingly common, averaging 27
(range, 7–57) per EAC. LOH and NLOH changes tended to be larger,
averaging 18 and 23 Mb, respectively, compared with 13 Mb for
gains (Supplementary Table S1). Within each sample, LOH and
NLOH changes were seen in an average of 20% of the genome, but
the range within individual EACs was very large (3–52%). These
changes often spanned a whole chromosome arm. It is noteworthy
that in some biopsies the majority of LOH changes tended to
involve all tumor cells, whereas others exhibited variable
proportions of tumor cell involvement. Examining the tumor panel
based on this variable revealed that it was variable, rather than
categorical, with most samples exhibiting some to many LOH
regions with <100% tumor cell involvement.
We noted 126 HDs within the EAC panel, ranging from 0 to 11 in
individual tumors (Supplementary Table S1). Of these, 29 (23%)
were partial HDs such that some DNA remained within a
proportion of tumor cells. This was determined manually using
SiDCoN (18) to show that the observed logR and Ballele pattern
resulted from mixed cell populations. Partial HDs generally arose
within a LOH or NLOH event, which perhaps demarks the initial
allelic loss. When the mixed populations included a combination of
HD, LOH, and normal cells or HD, NLOH, and normal cells, both
Figure 1. A region of chromosome 3p14.2 centered on the FHIT gene, viewed in the UCSC browser, May 2004 (hg17) build of the human genome. The custom
tracks represent profiles for 23 EAC biopsies with DNA copy number status noted by the shades: no fill, gain; light gray, NLOH; gray, LOH; black, HD.
Cancer Research
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Ballele and logR changes were used to determine the presence of
the HD. In some samples, partial HD events spanned up to 100 Mb;
however, HD regions in general were much smaller (<10 Mb) than
the other DNA copy number changes observed.
Considering the different DNA copy number changes outlined
above, the number of each type of change or the fraction of the
genome involved does not seem to relate to patient survival (all
CPH tests yielded P > 0.1) or tumor stage (P > 0.1, ANOVA).
Key regions of gain. It is worth noting that NLOH changes can
be considered, along with LOH, as the loss of a functional allele
(then duplication of the null/reduced allele) or with gains as a
duplication of an overactive oncogenic allele (and removal of the
normal allele). In this way, it is important to note NLOH changes
within regions of either high LOH or gain. Table 2B shows those
chromosomal regions with the most number of EAC biopsies
showing concomitant gain. The indicated regions represent the
smallest hg17 location shared among all amplified samples. It is
interesting that the region with the highest number of gains is
within 18q11.2, on a chromosome arm well documented as lost
in EAC. This is also the region in which we saw the most
amplifications, with 4 of the 14 gained samples showing greater
than five copies within 18q11.2. Although we also observed loss
further down the chromosome arm, this region of shared gain was
present in >60% of our samples and a further four EACs (17%) had
NLOH. The only known gene within the minimal region of overlap
between the 14 amplified samples (Table 2B) is CTAGE1 , which is
expressed in a variety of cancer types (20).
Chromosome 8 contained three key regions of gain (8q22.3-
8q24.21), each involving the same 13 (56%) biopsies. The individual
regions range in size from 1 to 3 Mb (Table 2B). The two smaller
regions, both in 8q24.21, seem to specifically target known
oncogenes (MYC, MLZE , and DDEF1), whereas the larger region
(8q22.3) contains several genes, including MYBL1 .
The EAC panel showed frequent gains on chromosome 20, most
commonly a 2.9-Mb section of 20q13.2. One sample, 40334, was
amplified spanning chr20:49397548-50700650, whereas 53048
showed a 4n gain at chr20:50788541-51029249 and strong (9n)
gain between chr20:51029250-52711041. The latter region contains
several genes, including the oncogene ZNF217 .
We observed two regions on the long arm of chromosome 1
with gains in >50% of EACs: chr1:143,700,001-144,900,000, centered
on BCL9 in 1q21.1, and chr1:151,700,000-152,300,000 in 1q22
(Table 2B). The latter region, defined by a 3n gain in 40334,
contains many genes, including MUC1 , which is known to have
oncogenic potential (21) and to be frequently overexpressed in
EACs (22).
Key regions of loss. We identified two types of LOH events
within our data, regions that include frequent HD events, such as
FHIT (Fig. 1), and areas of LOH with no accompanying HDs, such
as 17p (Supplementary Fig. S1), suggesting potentially different
mechanisms of action. Regions where two or more EAC biopsies
had overlapping HDs are shown in Table 3. All known genes that
map within each of these regions are listed. In several cases, for
example, FHIT (3p14.2), WWOX (16q23.2), DMD (Xp21.2),
MGC48628 (4q22.1), and PDE4D (5q11.2-q12.1), the smallest
region of overlap between the contributing samples can be
narrowed to within a gene. The smallest region of overlap within
FHIT is a 20- to 25-kb region within intron 4, defined by 17 HD
events (Fig. 1).
On chromosome 9p, six samples had HDs (Table 2E), which
overlapped such that the smallest region includes five genes: MTAP,
CDKN2A, CDKN2B, C9orf53 , and DMRTA1 (Supplementary Fig. S2).
Both CDKN2A and CDKN2B are recognized TSGs, and several
reports have noted CDKN2A deletions and mutations in EAC
(reviewed in refs. 9, 10). In our cohort, most HD events on
chromosome 9 clustered on 9p21.3, although 42199 has two
separate HD events [9p21.3 (chr9:20009316-22549868) and 9p21.2-
9p21.1 (chr9:27354350-30507289)] and a single HD in 40334 spans
9p21.1-pter (Supplementary Fig. S2).
We found three regions with HDs, 18q21.1, 18q21.32, and 18q23,
which center on a total of six genes (Table 3), two of which (SMAD4
and GALR1) are TSGs. Two EACs (40356 and 40364) had separate
HD events across 18q and two HD events span more than half the
telomeric end of these arms, further supporting the hypothesis that
there are multiple TSGs in this region.
Our analysis specifically identified MGC48628 (4q21.1) as a
potential TSG, with three (40345, 40358, and 42199) of five HDs
mapping within, or exclusively including, this gene. Six other
samples had LOH across MGC48628 , two more switched from
NLOH to LOH within it, whereas another EAC was NLOH across
the gene.
Table 2C presents a broad region of frequent LOH on
chromosome 5q (5q11.2-q14.3), whereas Table 2E shows three
HDs that focus on PDE4D (at the border or 5q11.2-q12.1). In the
latter region, 15 of 23 EACs had either LOH or HD, and two others
showed NLOH. By comparison, 10 samples had LOH for APC,
whereas 4 had NLOH for all, or part, of the gene.
Table 3 lists all HDs seen in two or more samples, and the
samples in which they occurred. None of the regions with two or
more HD samples (Table 3), nor all of them combined, provided
any evidence of association with patient survival (CPH) or tumor
stage (t test; data not shown).
Several regions contained high level of DNA loss but few HDs.
The most prominent of these was on chromosome 17p, where all
23 EACs showed LOH (Table 2C) or NLOH (Table 2D) changes for
most of the short arm, spanning chromosomal bands 17p12-p13.2
(Supplementary Fig. S1). Historically, TP53 (17p13.1) is frequently
lost or mutated in EAC (10). Our data did not specifically
implicate TP53 ; in fact, the broad overlapping region of change
shown in Supplementary Fig. S1 suggested additional targets on
17p. Furthermore, the single HD event present on 17p did not
include TP53 . Given that several samples shifted back and forth
between LOH and NLOH, it is difficult to ascertain a more
defined target region. If we assume NLOH to be more important,
then the regions 442766-1386639 (which includes ABR and
TUSC5) and 6879962-7662915 (which includes BCL6B, TP53 , and
POLR2A) both contained 10 NLOH events and 13 LOH events
across the 23 EAC biopsies, whereas if we assume LOH to be
more important the region chr17:12378912-15024426 (17p12),
defined by sample 41299, included 16 LOH and 7 NLOH events.
The only HD detected on chromosome 17p (10868740-11363397)
targeted FLJ45455 and there were 15 LOH and 7 NLOH events
across the same region.
Within chromosomal band 11p15.4, there were two small
adjacent regions (283572-10868740 and 10868740-21670355) with
14 LOH, 3 NLOH, and no HD and 15 LOH, 2 NLOH, and no HD
events, respectively.
Averaged gain/loss plots. Figure 2 shows median logR values
across each chromosome. The black line shows the median values,
whereas the gray margins demark the 75% (upper quartile) and 25%
(lower quartile) levels across all 23 samples. This format allows for
more direct comparison of our results to those of the previous CGH
Genome-Wide Copy Number Analysis in EAC
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and LOH studies because NLOH events were not highlighted. Using
a median gain of >0.2 as a cutoff (with a value of 0.33 indicating all
cells show a 3n complement for that DNA fragment), we found
gains on 1q, 2q, 7p, 8q, 12p, 13q, 18q, 20p, and 20q. Peak median
gains (>0.27) occurred at 8q23.3 (chr8:113800000-113900000) within
the CSMD3 gene, where 11 samples were amplified, and on
13q12.13 (chr13:24660000-24680000) near FLJ25477 , where 8 sam-
ples were amplified.
The sharply defined losses on chromosomes 3p and 9p, with
median logR values of less than 0.35 (Fig. 2), corresponded to HDs
within FHIT and 9p21.3 (containing CDKN2A and CDKN2B ; Fig. 1;
Supplementary Fig. S2). The region surroundingWWOX on 16q was
evident from the combined data (Fig. 2) but not to the same extent
due to the large number of NLOH events rather than the relatively
high number of LOH changes seen on 9p. Other extended regions of
loss, with median values of less than 0.2, mapped to 4p, 4q, 5q,
11p, 16p, 17p, 18q, 19p, and 22q (Fig. 2).
By using >0.3 for the 75% quartile level and less than 0.3 for the
25% level, we have flagged regions altered in a minority (f25%) of
samples. This added gains on 3q and 5p and deletions of 16q, 21q,
and Xp. Table 4 summarizes these data across all chromosome
arms, incorporating evidence drawn from previous CGH and LOH
genome-wide DNA copy number studies done on EACs, which is
discussed in detail below.
Discussion
Previous studies reported a high background rate of DNA copy
number change (20–30%) in EAC. We found a similar rate (40%)
when one considers that about one third of the changes we
observed are NLOH events, not detected by previous CGH studies.
In Table 4, the highlighted regions summarized for each study
indicate either gain (AMP), loss (LOH), or allelic imbalance (AI) in
Gleeson and colleagues (23), who did not distinguish loss and gain
events. Given this high background rate, it is not surprising that
only 10p and 18p (along with most acrocentric arms) show no
highlighted regions in any of the 10 studies (Table 4). Adopting a
pragmatic approach, we believe further investigation is required
into all chromosomal regions where three studies or less have
reported frequent changes. Important EAC genes may lie within
Table 3. Regions with 2 or more HDs within 23 EAC biopsies
Minimal HD
regions
Chromosomal
band
No.
HDs
chr3:60,310,
078-60,
712,164
3p14.2 17                 
chr16:76,691,
052-77,
804,064
16q23.2 8        
chr9:21,580,
000-22,
600,000
9p21.3 6      
chrX:30,898,
403-32,
989,184
Xp21.2 6      
chr4:91,513,
360-92,
060,333
4q22.1 5     
chr18:46,700,
000-46,
950,000
18q21.1 4    
chr18:72,900,
000-73,
900,000
18q23 4    
chr5:58,306,
241-59,
819,647
5q11.2-
q12.1
3   
chr18:56,
050,001-56,
400,000
18q21.32 3   
chr9:24,300,
000-25,
800,000
9p21.3-
p21.2
2  
chr20:14,500,
000-15,
536,000
20p21.1 2  
chr21:21,
500,001-25,
000,000
21q21.1-
q21.2
2  
4
0
3
2
0
4
0
3
2
3
4
0
3
2
5
4
0
3
3
1
4
0
3
3
4
4
0
3
3
8
4
0
3
4
0
4
0
3
4
1
4
0
3
4
5
4
0
3
5
3
4
0
3
5
6
4
0
3
5
8
4
0
3
5
9
4
0
3
6
0
4
0
3
6
1
4
0
3
6
2
4
0
3
6
3
4
0
3
6
4
4
2
1
9
9
5
3
0
4
8
5
3
1
4
5
5
4
0
1
4
5
4
0
4
3
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these regions; however, a much larger sample size would be
required to clarify whether genes within these regions play a
significant role in EAC etiology.
Given the strength of the 3p14 findings from our cohort (>70%
HD within FHIT) and others (24), it is surprising that only three of
the other nine studies in Table 4 report noteworthy LOH on
chromosome 3p. A partial explanation may lie in the fact that, of
the 22 samples in our study that showed loss on 3p, only 8 show
extensive regions of loss (Fig. 1); thus, low-density studies, such as
that of Hammoud and colleagues (25) with only a single marker at
3p25, may have missed the peak region within FHIT . This does not
explain the data of Weiss and colleagues (26), however, where
concomitant CGH analysis of esophageal squamous cell carcinoma
showed high levels of 3p deletion (64%), yet only 4% of their 24
EACs showed deletion on 3p.
Similar to FHIT (FRA3B), WWOX (FRA16B) and DMD (FRAXC)
occur within common fragile sites. Our data also showed frequent
HD within the latter two genes. We found NLOH events to be
frequent on 16q, masking its potential significance in the median
logR plot (Fig. 2), and in previous CGH studies that could not detect
NLOH events. Furthermore, given the low resolution of micro-
satellite LOH studies listed in Table 4 (39–138 markers), it is also
likely that other studies would have missed intragenic deletions
within WWOX . Thus, it is unclear whether previous genome-wide
studies did not detect losses in common fragile sites or whether
these changes are only present in a subset of EACs. The group that
previously reported HDs within FHIT (24) also observed changes in
other fragile site genes WWOX (FRA16D) and genes within FRAXB
(27). Because deletions targeting FRAXB have no known relevance
to EAC tumor biology, Arlt and colleagues (27) propose that the
increased activity of these fragile sites was a marker for genomic
instability. Several lines of evidence link common fragile site
stability to cell cycle checkpoints and DNA repair (reviewed in ref.
28). This does not negate the importance that loss of known TSGs
FHIT and WWOX (reviewed in ref. 28, 29) could have on the
progression of tumors with these changes; in fact, data indicate that
these genes and the fragile sites they arise in are co-conserved
(reviewed in ref. 29). Further work is required to characterize this
phenomenon, to determine whether it is restricted to a subset of
EAC patients, and to elicit specific roles for the disrupted genes.
The most consistent regions of frequent DNA loss in the
literature are on 4q, 5q, 9p, 17p, and 18q, with particular foci on
4q22, 5q21, 9p21, 17p12, and 18q21-22 (Table 4; reviewed in ref. 9).
On 4q, our cohort has highlighted MGC48628 (4q21.1) with 56%
LOH and three of five HDs involving only this gene. MGC48628
maps within the minimal region of loss identified by Rumpel and
colleagues (30) in 29 primary EAC tumors. Six other genome-wide
studies (Table 4) support frequent 4q LOH; however, within these,
there are two regions of loss: 4q22-23 (12, 13, 31) and 4p34-35 (11,
23, 25). Sterian and colleagues (32) reported frequent LOH on 4q,
focused on 4q31-35. Taken together, these data suggest multiple
target genes on this arm. Our median sample data (Fig. 2) showed a
sharp trough at 4p22 (MGC48628) and a much broader region of
loss at the telomere of 4q (4q34-35).
Chromosome 5q also shows frequent losses in 70% of studies
(Table 4). The most common region of loss maps to 5q21, likely
targeting APC (11–13). These data are supported by several
microsatellite-based studies, which report >30% LOH in the vicinity
Figure 2. Median EAC biopsy logR values for chromosomes 1 to 22 and X. To generate this plot, the smoothseg algorithm (19) was applied to individual sample
data and median values (black ), across 23 EACs, were plotted in R. Top and bottom light lines, quartile values for each median value. Guide lines at 0.2 and 0.2
represent median value thresholds discussed in text, whereas light guides at 0.3 and 0.3 represent quartile thresholds.
Genome-Wide Copy Number Analysis in EAC
www.aacrjournals.org 4169 Cancer Res 2008; 68: (11). June 1, 2008
Table 4. DNA copy number loss and gain summary of 10 genome-wide EAC tumor studies
Reference Current
study
van Dekken
(12)
Riegman
(11)
Walch
(13)
Albrecht
(36)
Barrett
(44)
Gleeson
(23)
Hammoud
(25)
Varis
(31)
Weiss
(26)
Notes
Study
type
SNP-aCGH CGH CGH CGH aCGH
(287 genes)
43
MSATs
138
MSATs
39
MSATs
CGH CGH
No. EAC 23 28 30 30 18 20
(flow sorted)
17 27 18 24
1p AMP LOH
1q AMP LOH
2p AMP AMP f2p22.3
2q AMP AMP 2q33
3p LOH LOH LOH LOH 3p14.3
3q AMP AMP AMP AI AMP 3q26
4p LOH LOH AMP Broad 4p
4q LOH LOH LOH LOH AI LOH LOH Broad 4q
5p AMP AMP AMP
5q LOH LOH LOH LOH LOH AI LOH 5q11.2-q12.1,
5q21
6p AMP AMP Broad 6p
6q AI
7p AMP AMP AMP AMP AMP f7p12, fp15
7q AMP/LOH AMP AMP AMP 7q21
8p LOH 8p21
8q AMP AMP AMP AMP AMP AMP AMP 8q24.1
9p LOH LOH LOH LOH AMP/LOH LOH AI 9p21
9q AI AMP
10p
10q AMP AMP 10q25-26
11p LOH 11p15.5
11q AMP 11q22.3
12p AMP AI 12p13.1
12q AMP AI 12q21.1
13p
13q AMP LOH LOH AMP AMP 13q12 (AMP),
13q14-31
(LOH)
14p
14q LOH LOH LOH 14q31-32
15p
15q AMP AMP AMP AMP 15q25
16p LOH 16p13.3
16q LOH LOH LOH 16q23
17p LOH LOH LOH LOH LOH AI LOH LOH 17p12
17q AMP AMP AMP/LOH AMP AMP 17p11,
17q21
18p
18q AMP/LOH LOH LOH AMP LOH AI LOH LOH 18q11.2
(AMP),
18q21-q23
(LOH)
19p LOH
19q AMP
20p AMP AMP 20p12
20q AMP AMP AMP AMP AMP AMP 20q13.2-13.31
21p
21q LOH LOH 21q21
22p LOH
22q LOH LOH 22q13.32
Xp LOH
Xq AMP 23p21.1
Y ND LOH LOH LOH ND ND ND ND ND ND
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of APC (33, 34). In contrast, our EAC cohort shows LOH across much
of 5q, with particularly strong regions of loss at 5q11.2-q12.1 and
5q14.3-31.1 (Fig. 2). The only three HDs observed on 5q are clearly
centered on PDE4D, which borders on 5q11.2 and 5q12.1, supported
by losses in 65% of our cohort compared with <45% in the vicinity
of APC . Thus, PDE4D, rather than APC , seems to be the focus
of 5q losses in our EAC cohort. HDs have recently been reported
within PDE4D in lung adenocarcinoma (35), suggesting it is a
putative TSG.
The broad LOH peak we observed on 18q (Fig. 2) is also present
in six of the nine previous genome-wide reports in Table 4.
Although the peak region seems to be within 18q21-22, containing
the candidate TSGs DCC, SMAD2 , and SMAD4 , CGH studies report
frequent loss of whole arm (11–13). Within our cohort, we have
nine HDs on chromosome 18q, which tend to cluster at 18q21.1,
18q21.32, or 18q23, with several samples having multiple HD events
across the arm implicating SMAD4, GALR1 , and MC4R , whereas
DCC and SMAD2 fall outside critical HD events. We have identified
a small (100 kb) region of gain at 18q11.2 (Fig. 2), suggesting the
presence of both an oncogene as well as the one or more TSGs on
this arm. The only gene that maps within this AMP is CTAGE1 . An
array CGH (aCGH) study noted that 39% (7 of 18) of their EACs
were amplified for LAMA3 (36), 1.3 Mb telomeric of CTAGE1 .
Further specific investigations will be needed to verify CTAGE1 as a
potential oncogenic target.
CDKN2A is one of the most frequently deleted genes across
cancers, and it is most likely the target for LOH in 9p21, a frequent
change noted in 7 of the 10 genome-wide studies in Table 4. Our
data showed frequent (26%) HDs involving CDKN2A ; however, the
minimal region of overlap between the six HD events contained
four other genes, including CDKN2B , another TSG. Several studies
have shown losses, mutation, or hypermethylation of CDKN2A in
EAC (10, 37–39).
All 23 of the EAC biopsies in this study showed DNA copy
number variations along the length of the short arm of
chromosome 17, generally LOH or NLOH. Changes to TP53
(17p13.1) have been reported as frequent early events in EAC
progression (40). However, others have noted that also multiple
regions on 17p are the target of LOH events (41).
Three studies reported frequent Y chromosome loss in 40% to
76% of EACs (11–13). The underrepresentation of Y loss in Table 4
may be simply because so few studies have investigated it. Because
the HapMap 330K SNP chips do not include Y-specific markers, we
are unable to confirm this in our cohort. Given the strong male bias
for this cancer, detailed investigation of the Y chromosome is
warranted, especially because reintroducing Y has been shown
to suppress the tumorigenic potential of other human cancer
cells (42).
Table 4 shows that four to five genome-wide DNA copy number
studies reported frequent gains on 3q, 7p, 7q, 15q, and 17q. Of
these, our cohort has median logR peaks >0.2 on 3q and 7p.
Looking across studies, focal points at 3q26, 7q21, and 15q25 can be
determined. Although the regions on 7p are broad, 17q gains seem
to center on 17q11 or 17q21 in different studies. Unlike the above
listed regions, peak gains on 8q and 20q were very broad in our
EAC panel (Fig. 2), suggesting the presence of multiple oncogenes
and perhaps explaining why these were the most frequently
amplified regions across the 10 studies (Table 4). Focal points of
common gain across the studies can be narrowed to 8q24.1 and
20q13. The main target on 8q is believed to be MYC , although other
surrounding oncogenes (including MLZE, DDEF1 , and MYBL1) are
frequently amplified. A novel amplicon resulting in the over-
expression of CTSB has been shown in one study (43), indicating
that this too may be a target for 8q gain. On chromosome 20q,
candidate genes include ZNF217 (36) and MYBL2 , although the
latter gene is not within our peak region.
In summary, we have generated the most comprehensive
investigation of DNA copy number variation in EAC tumors to
date. Our data indicate that structural genetic changes are very
frequent events in EAC, with an average of 97 changes per tumor.
These changes constitute roughly even proportions of gain,
LOH, and NLOH events, which together spanned 20% to 90% of
the individual tumor genomes. HDs were relatively infrequent,
0 to 11 per tumor, and tended to be highly focused. We confirm
that deletion within FHIT is one of the most common events in
EACs (24). Frequent HDs within FHIT (3p14.3), WWOX (16q), and
DMD (Xp) suggest a role for common fragile sites in EAC etio-
logy; alternatively, decreased genomic stability may be a critical
marker for a subset of EAC tumors. Aside from FHIT, these
regions seem to be infrequent sites of loss in other EAC DNA
copy number studies. This may be an issue of technical sensitivity
(detection density) or it may indicate an as yet unidentified EAC
stratification. Our data also showed multiple HDs targeting
PDE4D (5q11.2-q12.1) and possibly SMAD4 (18q21.1) and GALR1
(18q23), which appear in the chromosomal regions frequently
lost in previous studies (Table 4). In addition, we found HDs
clustered within the gene MGC48628 (4q22.1), making it a
potential novel TSG.
Meta-analysis of the 10 genome-wide CGH and LOH studies
summarized in Table 4 indicates that the most common sites for
gain in EAC are 8q24 and 20q13. The broad peaks generally
observed in these regions suggest that multiple oncogenes are
involved and our results are consistent with this. Additionally, we
have identified a frequent, focused gain within 18q11.2, centered on
CTAGE1 . Across the 10 studies, regions on 4q, 5q, 9p, 17p, 18q, and
Y are the most frequently lost in EAC. The target genes seem to
include the TSGs APC (5q21), CDKN2A (9p21.3), and TP53 (17p12),
although other genes on 5q and 17p also seem to be critically lost.
The key genes on 4q, 18q, and Y have yet to be identified.
Comprehensive genomic profiling such as that presented here will
allow a more defined approach to identifying and characterizing
genes involved in EAC progression, offering the potential for
improved clinical tests and treatments.
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